ClinicalTrials.gg
RecruitingNCT07266545Updated Jun 22, 2026

RNA Editing as a Biomarker of Antidepressant Response in Unipolar and Bipolar Depression (EDIT-ANDRE)

A Phase 4 interventional study of Vortioxetine and Cariprazine (Augmentation Phase) in Unipolar Depression and Bipolar Depression, sponsored by Mayo Clinic. Recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-06-22.

Sponsored by Mayo Clinic · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
120
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies testing vortioxetine in Depressive Disorder — 1 open to participants now, 1 under way, none of them phase 3. Vortioxetine · Depressive Disorder.

Planned enrollment
7th of 10
120 · median 511
Started
2026
the only one that year
Phase 4
2 of 10
1 open now
Registered
10th of 10
by date
Lead sponsor
1 of 10
Mayo Clinic

Among the 10 studies testing vortioxetine in Depressive Disorder, this one is the 7th largest by planned enrollment, is the only one that started in 2026, is one of 2 in phase 4, and was the 10th registered.

Depressive Disorder

857 studies on the registry are indexed under Depressive Disorder; 160 are open to participants now.

Browse Depressive Disorder studies →

Open to participants now

1 of the 10 studies testing vortioxetine in Depressive Disorder is open now, in 1 country.

By country, each count listing its studies:

About vortioxetine

Vortioxetine: first FDA approval 2013 (TRINTELLIX), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 116 Depressive Disorder studies recruiting now, 44 (38%) set no upper age limit and 66 (57%) stop at 75 or younger; 24 take children under 18; 25 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing vortioxetine in Depressive Disorder, or all of them as a file.
02

Study summary

The purpose of this research is to understand how changes in RNA editing relate to treatment response in unipolar and bipolar depression.

03

Conditions studied

  • Unipolar Depression
  • Bipolar Depression
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants must meet all the following criteria to be eligible for the study:

  1. Adult females and males, aged 18-65 years
  2. Must have the capacity to understand study procedures, to comply with them for the entire length of the study, and to provide .
  3. Current major depressive episodes associated with MDD, BD-I, or BD-II, confirmed using the SCID-IV-CV. If a participant has already completed a structured diagnostic interview within the last 2 years or participated in any of the following studies and provided consent to use their information in future studies: (IRB 19-001722, IRB: 23-004500, IRB: 24-013228, IRB: 25-005856, IRB: 25-007244), those SCID results can be used for the EDIT-ANDRE study.
  4. Symptom severity score on the Quick Inventory for Depressive Symptomatology - Clinician (QIDS-C16) > 10.
  5. Ability to travel for assessment visits.
  6. Negative urine pregnancy test for people of
  7. People of childbearing potential must be using an acceptable method of during the study, such as hormonal contraception, intrauterine device, bilateral tubal ligation, partner's documented vasectomy, or complete abstinence from intercourse with childbearing potential, with barrier methods permitted only when used in combination with one of these primary methods.
  8. BD-I patients must be on stable dose of at least one mood stabilizer (i.e., lithium, valproate, or a mood-stabilizing atypical antipsychotic at least for one month) at the time of enrollment.

Patients with BD-II who enroll in the study while currently taking a mood stabilizer (including lithium, valproate, or lamotrigine) must have been on a stable dose of that medication for a minimum of one month before enrollment.

Exclusion criteria

Exclusion Criteria

All candidates meeting any of the following criteria at baseline will be excluded from study participation:

  1. Individuals who cannot understand English will not be enrolled because , study procedures, and interviews require comprehension of English.
  2. Inability to provide written, voluntary informed consent due to but not limited to being under conservatorship, guardianship, commitment, or currently undergoing involuntary psychiatric hospitalization.
  3. Failure to score at least 75% on a 4-item comprehension assessment related to study goals, risks, and benefits
  4. For BD-I: not having used at least one mood stabilizer (e.g., lithium, valproate, or mood-stabilizing antipsychotics) at a stable dose and within a therapeutically effective antimanic range for a minimum of one month.
  5. History of treatment- depression, defined as non-response to two or more antidepressant or mood-stabilizing regimens despite adequate dose, duration, and adherence during the current episode.
  6. Participants with active suicidal ideation, defined as a MADRS item #10 score greater than 4 or a "yes" response to item #4 (ideation with intent) or item #5 (ideation with plan) on the C-SSRS, will be excluded
  7. A medically serious suicide attempt within the past 6 months, defined as requiring emergency department evaluation, a medical procedure, or admission to a hospital (e.g., internal medicine, cardiology, or ICU)
  8. Current use of monoamine oxidase inhibitors or use within 14 days following discontinuation of a monoamine oxidase inhibitor
  9. Presence of mixed symptoms of depression, defined as a YMRS score ≥12
  10. Current use of any of the study medications (e.g., vortioxetine, or cariprazine) at the time of enrollment (previous use of these medications is acceptable)
  11. Prior reaction to any of the study medications or documented non-response to any of the study medications at the maximum therapeutic dose
  12. A history of seizure disorder
  13. Recent use of long half-life psychotropic medications, including fluoxetine (in patients with BD and MDD) and long acting injectable forms of antipsychotics (mainly in BD II and MDD) within the past 4 weeks.
  14. Active psychosis, defined as a YMRS item #8 score >4 or diagnosis of schizophrenia, schizoaffective disorder, delusional disorder, or schizophreniform disorder as determined by structured clinical interview
  15. Current drug or alcohol use disorder (excluding nicotine); full remission for at least 3 months is required for eligibility
  16. Positive toxicology screen for illicit substances (e.g., cocaine, methamphetamine, illegal opiates). Participants who use cannabis for recreational or medicinal purposes and fail the toxicology screen can potentially be included in the study only if they take the CUDIT-R and score a 12 or less.
  17. Individuals who are pregnant, lactating, trying to conceive, or not using adequate (e.g., hormonal contraception, intrauterine device, tubal ligation, or condoms)
  18. Any active or unstable medical condition judged by the principal investigator to confer excessive risk
  19. laboratory abnormality, uncontrolled hypertension (blood pressure >160/100 mmHg), or tachycardia (heart rate >110 bpm)
  20. Significant renal, hepatic, or cardiac disease; ; disease; or chronic kidney disease > stage IIIa (estimated \< 60 mL/min/1.73 m²)
  21. History of traumatic brain injury defined as loss of consciousness for 5 minutes and related to a trauma event
  22. Gastric bypass, specifically Roux-en-Y
  23. Clinical current diagnosis of delirium, encephalopathy, intellectual disability or cognitive disorder (mild or major neurocognitive disorder)
  24. Currently receiving electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), vagus nerve stimulation (VNS), or deep brain stimulation (DBS) as acute or maintenance treatment
  25. Current use of systemic , chemotherapy, and radiotherapy
  26. Daily use of lorazepam (Ativan) >4 mg/day, or equivalent doses of other benzodiazepines (e.g., clonazepam >1 mg, alprazolam >2 mg, diazepam >20 mg)
  27. No access to smartphones, internet
  28. Other Axis I or II diagnoses, by clinical judgments that are the current reason for treatment evaluation or play a large part of the current symptom presentation
  29. Ongoing treatment with opioid agonists will constitute an exclusion criterion. In contrast, other ongoing treatments, such as alcohol relapse prevention agents or ADHD pharmacotherapy, will not be considered exclusion criteria, provided that no treatment initiation or significant dose adjustment has occurred within the past 4 weeks.

All candidates meeting any of the following criteria at baseline will be excluded from the Phase 2 (cariprazine add-on) of the study:

  1. Meeting symptomatic remission criteria based on MADRS (≤ 10).
  2. Current use of a strong or moderate inhibitor (e.g., ketoconazole, clarithromycin, fluconazole, or verapamil) strong or moderate CYP3A4 inducer (e.g., carbamazepine, rifampin, phenytoin, or St. John's Wort), due to potential pharmacokinetic interactions with cariprazine.
  3. Diagnosis of BD-I with concurrent use of an antipsychotic agent as a mood stabilizer.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Vortioxetine

    Subjects will be started on vortioxetine for 8 weeks of treatment with vortioxetine at 10 mg/day, titrated to 20 mg/day (after 7 days). Subjects who do not meet remission criteria will enter a second 8 week augmentation phase.

    Drug: Vortioxetine · Drug: Cariprazine (Augmentation Phase)

Interventions

  • Vortioxetine, once daily, for 8 weeks

  • DrugCariprazineStudies of CariprazineCariprazine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants who do not meet remission criteria will enter a second 8-week augmentation phase (Weeks 9-16). During this phase, cariprazine will be added to the existing regimen, administered orally once daily in the morning, starting at 1.5 mg/day and titrated up to 3.0 mg/day in one week.

06

What researchers measure

Primary outcomes

  1. Change in Montgomery-Åsberg Depression Rating Scale (MADRS) score

    The Montgomery-Åsberg Depression Rating Scale (MADRS) is scored on a scale of 0 to 60, with each of the 10 items rated from 0 to 6 by a trained clinician during an interview. A higher score indicates a more severe level of depression, with common severity ranges being: 0-6 (normal), 7-19 (mild), 20-34 (moderate), and 35-60 (severe).

    Time frame: Baseline, Week 2, Week 8, Week 10, Week 16

07

Study locations

1 of 1 sites recruiting
  • Mayo Clinic in Rochester
    Rochester, Minnesota 55905, United States
    Recruiting
    • Scott E. Feeder · Contact507-255-1975
    • Aysegul Ozerdem, MD, PhD · Principal investigator
    • Deniz Ceylan, MD, PhD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2026 (actual). Primary completion is estimated for Dec 2028, 34 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 25, 2025
First posted
Dec 5, 2025
StartActual
Feb 17, 2026
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2030
Last update
Jun 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07266545
Lead sponsor
Mayo Clinic
Responsible party
Aysegul Ozerdem (Principal Investigator, Mayo Clinic) — Principal investigator
First posted
Dec 5, 2025
Start date
Feb 17, 2026
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Jun 22, 2026

Study contacts

Scott E. Feeder
Contact
feeder.scott@mayo.edu
507-255-1975
Aysegul Ozerdem, MD, PhD
principal investigator · Mayo Clinic
Deniz Ceylan, MD, PhD
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Vortioxetine · Cariprazine

Start the discussion